HuCAL

Type: Product
Name: HuCAL
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext: GLPG; OTC: GLPYY) announced today that the first program from their strategic alliance has advanced into preclinical development. MOR106 ... [Published Virtual Strategy Magazine - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

MorphoSys to Host Q2 2014 Conference Call on 28 July 2014

World News: 13:35 GMT Monday 21st July 2014 . [ ]This storyMARTINSRIED / MUNICH, Germany, July 21, 2014 (GLOBE NEWSWIRE)MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2014 results on 28 July 2014 at 7:00 am ... [Published SPi World News - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

MorphoSys Receives Additional Patents on Novel Antibody Platform Ylanthia in the US and First Patent in China

MorphoSys AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and Trademark ... [Published BusinessWeek - Jul 18 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Lois Laxton dancers ready for Spanish fiesta

| Photo by Mike PearsonCompetitive dancers from Lois Laxton Dance Studio will showcase their skills in Spain this month.By Mike Pearson, News staffIt’s known for its scenic shoreline, the gardens of La Paloma and its cable car views of the Calamorro ... [Published Stoney Creek News - Jul 10 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Monoclonal antibodies against ANGPTL3

Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are ... [Published PharmCast - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Hamilton Catholic board celebrates excellence in education

Mac Christie, ReviewBishop Tonnos Catholic Secondary School alumni and 2014 Olympic gold medal-winning women's hockey player Laura Fortino (centre) recieves a special award from director of education Patricia Amos (left) and board chairperson Pat Daly ... [Published Flamborough Review - Jun 16 2014]
First reported Feb 18 2014 - Updated Feb 19 2014 - 1 reports

MorphoSys gets clinical milestone from Novartis in anti-inflammatory programme

MorphoSys AG, one of the world's leading biotechnology companies focusing on fully human antibodies, has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a phase I clinical ... [Published PharmaBiz - Feb 18 2014]

Quotes

"It is gratifying that the first development program from our alliance with Galapagos has entered the preclinical development stage. The novel mode of action for MOR106 remains undisclosed. Furthermore, we are applying Ylanthia in a growing number of existing and new alliances and an increasing proportion of our pipeline is based on this next-generation platform" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG
"Our new antibody platform Ylanthia is being used in a rising number of therapeutic relationships including our recent alliances with Merck Serono and Temple University. In addition to building a track record on the commercial side, robust patent protection is important for our new technology platform and today's patents further strengthen our position around Ylanthia in our core markets and in the emerging markets" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG
...and biotech companies that we expect to see during the course of the year," commented Dr Marlies Sproll, chief scientific officer of MorphoSys AG. "In total, our collaboration with Novartis has resulted in eight clinical antibodies to date, three currently being in phase I development, four in phase II and one in a pivotal trial."

More Content

All (7) | News (7) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
MorphoSys and Galapagos Advance Joint Antibody ... [Published Virtual Strategy Magazine - Jul 23 2014]
MorphoSys to Host Q2 2014 Conference Call on 28... [Published SPi World News - Jul 21 2014]
MorphoSys Receives Additional Patents on Novel ... [Published BusinessWeek - Jul 18 2014]
Lois Laxton dancers ready for Spanish fiesta [Published Stoney Creek News - Jul 10 2014]
Monoclonal antibodies against ANGPTL3 [Published PharmCast - Jun 17 2014]
Hamilton Catholic board celebrates excellence i... [Published Flamborough Review - Jun 16 2014]
MorphoSys gets clinical milestone from Novartis... [Published PharmaBiz - Feb 18 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.